Abstract
Background: Huntington′s Disease (HD) is an inherited neurodegenerative disorder characterised by progressive cognitive and motor decline largely due to the loss of striatal medium spiny neurons in the basal ganglia. No disease–modifying therapies exist, but novel clinical trials are ongoing. Non–invasive imaging biomarkers sensitive to HD neuropathology are essential for evaluating therapeutic effects. Soma and Neurite Density Imaging (SANDI), a multi–shell diffusion–weighted imaging model, estimates intracellular signal fractions from sphere–shaped soma in grey matter. SANDI–derived apparent soma density and size in the striatum have potential as proxies for HD–related neurodegeneration. Objective: To characterise HD–related microstructural abnormalities in the basal ganglia using SANDI and examine associations between SANDI indices, volumetric measurements, and motor performance. Methods: T1–weighted anatomical and multi–shell diffusion–weighted images (b–values: 200–6,000 s/mm2) were acquired using a 3T Siemens Connectom scanner (300mT/m) in 56 HD gene–positive individuals (41 premanifest) (Mean Age = 46.1, SD Age = 13.8, 25 females) and 57 healthy controls (Mean Age = 45.0, SD Age = 13.8, 31 females). Gene–positive participants completed Quantitative Motor (Q–Motor) tasks, including speeded and paced finger tapping, which were reduced to one motor performance component. Following standard diffusion–weighted data preprocessing, SANDI and diffusion tensor models estimated apparent soma density, soma size, neurite density, extracellular signal fraction, fractional anisotropy, and mean diffusivity. The caudate, putamen, pallidum, and thalamus were segmented bilaterally, and microstructural and volumetric indices were extracted and compared. Correlations between SANDI indices, Q–Motor performance, and volumetric measures were analysed. Results: HD was associated with reduced apparent soma density (r = 0.32, p ≤ 0.007) and increased apparent soma size (r = -0.45, p < 0.001) and extracellular signal fraction (r = -0.34, p ≤ 0.003) in the basal ganglia, but not the thalami. No differences were found in apparent neurite density (r = -0.18, p = 0.17). Previously reported HD–related increases in fractional anisotropy and mean diffusivity in the basal ganglia were replicated. Q–Motor component scores correlated negatively with apparent soma density and positively with soma size and extracellular signal fraction. SANDI indices and age explained up to 63% of striatal atrophy in HD. Conclusion: SANDI measures detected HD–related neurodegeneration in the striatum, accounted significantly for striatal atrophy, and correlated with motor impairments. Decreased apparent soma density and increased soma size align with ex vivo evidence of medium spiny neuron loss and glial reactivity. SANDI shows promise as an in vivo biomarker and surrogate outcome measure for HD–related neurodegeneration in clinical trials.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a National Institute for Health Research (NIHR) and Health and Care Research Wales (HCRW) Advanced Fellowship to CMB (grant number: NIHR-FS(A)-2022). The Centre for Trials Research at Cardiff University receives infrastructure funding from HCRW. MP is supported by the UKRI Future Leaders Fellowship MR/T020296/2.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was ethically approved by the Wales Research Ethics Committee 2 (REC Reference: 22/WA/0147). Cardiff University is the sponsor of this research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.